Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 5Breast Neoplasms 3Prostatic Neoplasms 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1MMR-D/MSI-H Colorectal Cancers 1Lymphoma 1Leiomyosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 6Cisplatin 5infigratinib 2Platinum 2Fluorouracil 21,2-diaminocyclohexaneplatinum II citrate 2ricolinostat 1niraparib 1lenvatinib 1galactomannan 1fludarabine 1famitinib 1dostarlimab 1atezolizumab 1aldesleukin 1Taxes 1Standard of Care 1Sildenafil Citrate 1Sevoflurane 1Photochemotherapy 1Oxaliplatin 1Observation 1NVP-BKM120 1Interviews as Topic 1IMC-001 1Electroporation 1Desflurane 1Cyclophosphamide 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Cholangiocarcinoma × niraparib × Clear all
NCT04895046 2022-06-29

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Hoosier Cancer Research Network

Phase 2 Withdrawn
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡